KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Goodwill (2020 - 2023)

Bionano Genomics (BNGO) has disclosed Goodwill for 4 consecutive years, with $77.3 million as the latest value for Q2 2023.

  • Quarterly Goodwill rose 37.38% to $77.3 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $77.3 million through Jun 2023, up 37.38% year-over-year, with the annual reading at $77.3 million for FY2022, 37.62% up from the prior year.
  • Goodwill hit $77.3 million in Q2 2023 for Bionano Genomics, roughly flat from $77.3 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $77.3 million in Q4 2022 to a low of $6.9 million in Q3 2020.
  • Historically, Goodwill has averaged $41.1 million across 4 years, with a median of $56.2 million in 2021.
  • Biggest five-year swings in Goodwill: grew 3.34% in 2021 and later skyrocketed 687.2% in 2022.
  • Year by year, Goodwill stood at $7.2 million in 2020, then skyrocketed by 682.94% to $56.2 million in 2021, then skyrocketed by 37.62% to $77.3 million in 2022, then fell by 0.01% to $77.3 million in 2023.
  • Business Quant data shows Goodwill for BNGO at $77.3 million in Q2 2023, $77.3 million in Q1 2023, and $77.3 million in Q4 2022.